Agenus delivers 33 percent three year OS in MSS mCRC trial with BOT plus BAL

Agenus delivers 33 percent three year OS in MSS mCRC trial with BOT plus BAL
Agenus posts new mCRC trial data

Agenus has released new three year follow up data from its ongoing study evaluating the investigational combination of BOT plus BAL in patients with refractory microsatellite stable metastatic colorectal cancer (MSS mCRC) without active liver metastases.

The data show an overall survival rate of 33 percent at three years, with a median overall survival of 21.2 months and no new safety signals reported. This update was presented at the ESMO Gastrointestinal Congress 2026. Links to the company release and scientific poster were made available for further details.

Agenus and the Armenian Bioinformatics Institute previously announced findings on immune patterns in MSS colorectal cancer using transcriptomics. The study focused on immune signatures observed in so-called cold tumors. These earlier data provide context for the ongoing investigation of BOT plus BAL in treatment-resistant patient populations.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.